Ribavirin 200 mg Tablets Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of ribavirin 200 mg
tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA
Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult,
non-smoking, females (who are unable to become pregnant) under non-fasting conditions.